Abstract
Zusammenfassung. Wir stellen Fälle von Patientinnen und Patienten mit erhöhtem Gesamtcholesterin vor, die eine alternative Therapie zur herkömmlichen Medikation der Cholesterin-Senkung anwenden wollten. Bei allen Personen konnte eine Verbesserung des Lipidprofils festgestellt werden, wobei alle das aus Roter Reishefe hergestellte Produkt sehr gut vertragen haben. Nebenwirkungen konnten nicht festgestellt werden. Die Patientinnen und Patienten, die dieses Produkt aus rot fermentiertem Reis einnehmen, wählen bewusst ein alternatives Mittel aus dem Bereich der Phytotherapie, weil sie meist schon mehrere schulmedizinische Medikamente einnehmen müssen und nicht mehr bereit sind, ein weiteres Medikament dieser Art zu verwenden. Ein weiterer Grund ist, dass sie die Nebenwirkungen nicht mehr in Kauf nehmen möchten, unter denen sie bei der Einnahme eines gängigen Lipidsenkers gelitten haben.
Abstract. We present cases of patients with high total cholesterol who wanted to use an alternative therapy for lowering cholesterol. An improvement in the lipid profile was found in all patients, and all tolerated the product made from red rice yeast very well. No side effects were observed. The patients who take red fermented rice consciously choose an alternative agent in the field of phytotherapy because they already have to take several conventional medicines and are no longer willing to use an additional drug of this kind. Another reason is that they no longer want to put up with the side effects they suffered from when using a common lipid-lowering drug.
Résumé. Nous présentons des cas de patients ayant un taux de cholestérol total élevé qui souhaitaient utiliser une thérapie alternative aux médicaments conventionnels pour réduire le cholestérol. Une amélioration du profil lipidique a été observée chez tous les patients, et tous les patients ont très bien toléré le produit à base de levure de riz rouge. Aucun effet secondaire n’a été trouvé. Les patients qui prennent ce produit sur du riz fermenté rouge choisissent consciemment un agent alternatif dans le domaine de la phytothérapie car ils doivent souvent prendre plusieurs médicaments conventionnels et ne veulent plus utiliser un autre médicament de ce type. Une autre raison est qu’ils ne veulent plus supporter les effets secondaires dont ils ont souffert lors de l’utilisation d’un médicament hypolipidémiant courant.
Bibliografie
, Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet. 2015;385:2264–2271.
. Statin-induced myopathies. Pharmacol Rep. 2011;63:859–866.
. Red yeast rice preparations: Are they suitable substitutions for statins? Am J Med 2017;130:1148–1150.
.Red yeast rice. Foods. 2017;6:19.
. Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. Am J Clin Nutr. 1999;69:231–236.
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) . Scientific Opinion on the substantiation of health claims related to monacolin K from red yeast rice and maintenance of normal blood LDL cholesterol concentrations (ID 1648, 1700) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2011;9:2304., Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia. Life Sci. 2004;74:2129–2142.
. Clinical and research information on drug-induced liver injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. 2012–2018; June 4.
. Bencao Gangmu: Compendium of Materia Medica. 1. Aufl. Beijing; Foreign Languages Press:2003.
. Modern Food Additive Standards of the Chinese Ministry of Public Health. National Standard GB. 1982;27078-27063-8:1982.
Swissmedic . Vermarktung von Präparaten mit Monascus purpureus (Rotschimmelreis, rote Reishefe) ist in der Schweiz nicht zulässig. 2019. https://www.swissmedic.ch/swissmedic/de/home/services/delimitation/humanpraeparate.html; letzter Zugriff: 28.06.2020.. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apolipoprotein B synthesis. J Clin Invest. 1987;80:1692–1697.
, An overview of the bioactivity of monacolin K / lovastatin. Food Chem Toxicol. 2019;131:110585.
. The role of red yeast rice for the physician. Curr Atheroscler Rep. 2011;13:73–80.
. A renewed focus on the association between thyroid hormones and lipid metabolism. Front Endocrinol (Lausanne). 2018;9:511.
. Low normal thyroid function as a determinant of increased large very low density lipoprotein particles. Clin Biochem. 2015;48:489–494.
, . Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc. 2008;83:758–764.
. Xuezhikang decreases serum lipoprotein(a) and C-reactive protein concentrations in patients with coronary heart disease. Clin Chem. 2003;49:1347–1352.
. Characterization of dehydromonacolin-MV2 from Monascus purpureus mutant. J Appl Microbiol. 2007;103:2168–2173.
. Isolation and characterization of dihydromonacolin-MV from Monascus purpureus for antioxidant properties. Appl Microbiol Biotechnol. 2007;73:1197–1202.
. New anti-inflammatory and anti-proliferative constituents from fermented red mold rice Monascus purpureus NTU 568. Molecules. 2010;15:7815–7824.
. Benefit of Monascus-fermented products for hypertension prevention: a review. Appl Microbiol Biotechnol. 2012;94:1151–1161.
, Chinese red yeast rice attenuates the development of angiotensin II-induced abdominal aortic aneurysm and atherosclerosis. J Nutr Biochem. 2012;23:549–556.
. Protective effect of Monascus-fermented red mold rice against alcoholic liver disease by attenuating oxidative stress and inflammatory response. J Agric Food Chem. 2011;59:9950–9957.
. Ankaflavin: a natural novel PPARγ agonist upregulates Nrf2 to attenuate methylglyoxal-induced diabetes in vivo. Free Radic Biol Med. 2012;53:2008–2016.
. Monascin improves diabetes and dyslipidemia by regulating PPARγ and inhibiting lipogenesis in fructose-rich diet-induced C57BL/6 mice. Food Funct. 2013;4:950–959.
. Red mold, diabetes, and oxidative stress: a review. Appl Microbiol Biotechnol. 2012;94:47–55.
. The Monascus metabolite monascin against TNF-α-induced insulin resistance via suppressing PPAR-γ phosphorylation in C2C12 myotubes. Food Chem Toxicol. 2011;49:2609–2617.
. Red mold fermented products and Alzheimer’s disease: a review. Appl Microbiol Biotechnol. 2011;91:461–469.
. Red mold rice extract represses amyloid beta peptide-induced neurotoxicity via potent synergism of anti-inflammatory and antioxidative effect. Appl Microbiol Biotechnol. 2008;79:829–841.
. Red mold rice promotes neuroprotective sAPPalpha secretion instead of Alzheimer’s risk factors and amyloid beta expression in hyperlipidemic Abeta40-infused rats. J Agric Food Chem. 2010;58:2230–2238.
. Red mold rice ameliorates impairment of memory and learning ability in intracerebroventricular amyloid beta-infused rat by repressing amyloid beta accumulation. J Neurosci Res. 2007;85:3171–3182.
. Neurocytoprotective effects of aliphatic hydroxamates from lovastatin, a secondary metabolite from Monascus-fermented red mold rice, in 6-hydroxydopamine (6-OHDA)-treated nerve growth factor (NGF)-differentiated PC12 cells. ACS Chem Neurosci. 2015;6:716–724.
. Cholestin inhibits cholesterol synthesis and secretion in hepatic cells (HepG2). Mol Cell Biochem. 2002;233:153–158.
. Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials. Chin Med. 2006;1:4.
. Low daily dose of 3 mg monacolin K from RYR reduces the concentration of LDL-C in a randomized, placebo-controlled Intervention. Nutr Res. 2016;36:1162–1170.
, . A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One 2014;9:e98611.
. Red yeast rice lowers cholesterol in physicians – a double blind, placebo controlled randomized trial. BMC Complement Altern Med. 2013;13:178.
. Efficacy and safety of Monascus purpureus went rice in children and young adults with secondary hyperlipidemia: a preliminary report. Eur J Intern Med. 2009;20:e57–61.
. Efficacy and safety of Monascus purpureus Went rice in subjects with secondary hyperlipidemia. Clin Exp Nephrol. 2008;12:189–194.
. Efficacy and safety of Monascus purpureus went rice in subjects with hyperlipidemia. Eur J Endocrinol. 2005;153:679–686.
. A systematic review of xuezhikang, an extract from red yeast rice, for coronary heart disease complicated by dyslipidemia. Evid Based Complement Alternat Med. 2012;2012:636547.
, Chinese Coronary Secondary Prevention Study Group, Li S. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol. 2008;101:1689–1693.
, China Xuezhikang, an extract of cholestin, reduces cardiovascular events in type 2 diabetes patients with coronary heart disease: subgroup analysis of patients with type 2 diabetes from China coronary secondary prevention study (CCSPS). Coronary Secondary Prevention Study (CCSPS). J Cardiovasc Pharmacol. 2007;49:81–84.
, . Chinese Coronary Secondary Prevention Study Group. Beneficial impact of Xuezhikang on cardiovascular events and mortality in elderly hypertensive patients with previous myocardial infarction from the China Coronary Secondary Prevention Study (CCSPS). J Clin Pharmacol. 2009;49:947–956.
, Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance. Am J Cardiol. 2010;105:198–204.
. Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial. Ann Intern Med. 2009;150:830–839.
. Mini-review: medication safety of red yeast rice products. Int J Gen Med. 2019;12:167–171.
. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002;36:288–295.
. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1998;63:397–402.
. Acute administration of red yeast rice (Monascus purpureus) depletes tissue coenzyme Q(10) levels in ICR mice. Br J Nutr. 2005;93:131–135.
. Acute liver injury induced by red yeast rice supplement BMJ Case Rep. 2019;12:e227961.
. Red yeast rice as the presumed cause of acute kidney and liver failure. Ugeskr Laeger. 2019;181:V02190107.
. Red yeast rice: An unsafe food supplement? Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2017;60:292–296.
. Safety and efficacy of red yeast rice (Monascus purpureus) as an alternative therapy for hyperlipidemia. P T. 2009;34:313–327.
. Red yeast rice preparations: are they suitable substitutions for statins? AM J Med. 2017;130:1148–1150.
. Rhaybdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation. 2002;74:1200–1201.
. Pharmacologically effective red yeast rice preparations marketed as dietary supplements illustrated by a case report. Drug Test Anal. 2016;8:315–318.
. Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system. Br J Clin Pharmacol. 2017;83:894–908.
BfR . Cholesterinsenkung mit Folgen: Nahrungsergänzungsmittel mit Rotschimmelreis nur nach ärztlicher Rücksprache einnehmen. 2020. https://mobil.bfr.bund.de/cm/343/cholesterin senkung-mit-folgen-nahrungsergaenzungsmittel-mit-rotschimmelreis-nur-nach-aerztlicher-ruecksprache-einnehmen.pdf; letzter Zugriff: 28.06.2020.DFG Senatskommission zu gesundheitlicher Bewertung von Lebensmitteln . Toxikologische Bewertung von Rotschimmelreis: Aktualisierung. 2012. www.dfg.de/download/pdf/dfg_im_profil/reden_stellungnahmen/2012/sklm_rotschimmelreis_121218.pdf; letzter Zugriff: 28.06.2020.BVL/BfArM . Stellungnahme der Gemeinsamen Expertenkommission BVL/BfArM. Einstufung von Rotschimmelreisprodukten (02/2016). 2016. https://www.bfarm.de/SharedDocs/Downloads/DE/Arzneimittel/Zulassung/ZulRelThemen/abgren zung/Expertenkommission/stellungnahmen/2016-02.pdf?__blob=publicationFile&v=15; letzter Zugriff: 28.06.2020.
